Quantum Biopharma to Jointly Study Demyelination Imaging Technique With Massachusetts General Hospital

, MT Newswires -  4:23 AM ET 4/1/2025 Company News

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

04:23 AM EDT, 04/01/2025 (MT Newswires) -- Quantum Biopharma ( QNTM ) said Tuesday it entered into a joint clinical study with the Massachusetts General Hospital to investigate an imaging technique to monitor demyelination in people suffering from multiple sclerosis.

The parties aims to validate a novel positron emission tomography, or PET, biomarker to monitor myelin integrity and measure demyelination. Multiple sclerosis is a chronic disease of the central nervous system.

The financial terms of the collaboration weren't disclosed.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.